Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid microparticles for mucosal immunization against hepatitis B.

Surbhi Saraf1, Dinesh Mishra, Abhay Asthana

  • 1Department of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar, Madhya Pradesh 470003, India.

Vaccine
|August 27, 2005
PubMed
Summary

Developing novel lipid microparticles for intranasal delivery of hepatitis B surface antigen (HBsAg) offers superior mucosal immunity compared to traditional methods. This approach enhances vaccine effectiveness against inhaled or ingested pathogens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adrenal Washout Under Scrutiny: Spectrum, Pitfalls, and Mimics.

Cureus·2026
Same author

Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation.

Journal of pharmaceutical sciences·2026
Same author

Intranasal nanoemulsion-based <i>in-situ</i> gel containing dexlansoprazole: formulation development, <i>in-vitro</i> and <i>ex-vivo</i> evaluation.

Drug development and industrial pharmacy·2026
Same author

Microbial lipids for a sustainable future: the growing potential of synthetic microbial engineering for consumer oils.

Critical reviews in biotechnology·2026
Same author

Generalism as a cross-disciplinary practice in medicine: Mixed-studies systematic review.

Canadian family physician Medecin de famille canadien·2026
Same author

Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy.

Advances in immunology·2025

Area of Science:

  • Immunology
  • Biomaterials Science
  • Vaccinology

Background:

  • Parenteral vaccine administration often fails to induce robust mucosal immunity, crucial for protection against inhaled or ingested pathogens.
  • Developing effective mucosal vaccines requires strategies that elicit strong and lasting immune responses at mucosal surfaces.
  • Hepatitis B surface antigen (HBsAg) is a key component for vaccines against Hepatitis B virus.

Purpose of the Study:

  • To develop and evaluate lipid microparticles (LM) for intranasal delivery of HBsAg to induce optimal mucosal immune responses.
  • To investigate the biocompatibility and mucoadhesive properties of soyalecithin-based LMs for mucosal vaccine applications.
  • To compare the immunogenicity of intranasally delivered HBsAg-loaded LMs with conventional vaccine formulations.

Main Methods:

Related Experiment Videos

  • Hepatitis B surface antigen (HBsAg) was encapsulated into lipid microparticles (LMs) using a double emulsion-solvent evaporation (w/o/w) technique.
  • Soyalecithin was utilized as a biocompatible and lung-surfactant-mimicking component for LM formulation.
  • Formulations were characterized for stability, mucoadhesion, and cellular uptake (ex vivo). In vivo immunogenicity was assessed via mucosal IgA response after intranasal (IN) or intramuscular (IM) administration.

Main Results:

  • Intranasal administration of HBsAg-loaded lipid microparticles (LMST-HBsAg IN) induced a significantly higher mucosal immune response (IgA) compared to intramuscular delivery or conventional alum-adjuvanted vaccines.
  • Lipid microparticle formulations demonstrated favorable mucoadhesion and cellular uptake characteristics.
  • The sequence of immune response potency was LMST-HBsAg (IN) > LM-HBsAg (IN) > alum-HBsAg (IN) > LMST-HBsAg (IM) = alum-HBsAg (IM) = LM-HBsAg (IM) > plain HBsAg (IN) = plain HBsAg (IM).

Conclusions:

  • Intranasal delivery of HBsAg-loaded lipid microparticles, particularly those incorporating soyalecithin, represents a promising strategy for enhancing mucosal immunity.
  • This novel delivery system offers a potential alternative to parenteral vaccination for achieving superior protection against mucosal pathogens.
  • Further development of these lipid microparticle-based mucosal vaccines could improve global health outcomes for vaccine-preventable diseases.